Warner-lambert Company

Reata Pharmaceuticals, Inc.

Patrick Michael O'Brien

Drago R Sliskovic

Joseph Armand Picard

Andrew David White

Bruce D Roth

William Chester Patt

Xin Jiang

Melean Visnick

Gary Louis Bolton

Helen Tsenwhei Lee

Michael William Wilson

Claude Forsey Purchase, Jr

Nicole Chantel Barvian

Eric Anderson

Daniel Fred Ortwine

Robert M Kral, Jr

Deborah A Ferguson

David T Connor

Amy Mae Bunker

Kevon Ray Shuler

Bradley W Caprathe

William Howard Roark

Chitase Lee

Christopher F Bender

William Glen Harter

Martha R Hotema

James Lester Hicks

Mark Anthony Morris

Ly Pham

Christopher Alan Conrad

Brian Kornberg

Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and RORγ. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.

Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma

This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, Rand Rare defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use

Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use

This invention provides compounds defined by Formula I and pharmaceutically acceptable salts thereof,and pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of treating osteo- and rheumatoid arthritis.

Hetero biaryl derivatives as matrix metalloproteinase inhibitors

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,wherein:

Pyridine matrix metalloproteinase inhibitors

The present invention provides compounds of formula (I) wherein R, Z, Y, W, R, V, and X are as defined in the description, and pharmaceutically acceptable salts thereof, which are useful for the treatment of diseases responsive to the inhibition of the enzyme 15-lipoxygenase. Thus, the compounds of formula (I) and their pharmaceutically acceptable salts are useful for treating diseases with an inflammatory component, including atherosclerosis, diseases involving chemotaxis of monocytes, inflammation, stroke, coronary artery disease, asthma, arthritis, colorectal cancer, and psoriasis.

1,2,4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase

The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

Method of inhibiting matrix metalloproteinases

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,

Growing community of inventors

Stockbridge, MI, United States of America

Patrick Michael O'Brien